Literature DB >> 25095748

Clinicopathological and prognostic significance of p53, Ki-67, and Bcl-2 expression in Tunisian gastric adenocarcinomas.

Dorra Ben Ayed1, Abdelmajid Khabir2, Mohamed Abid3, Mohamed Issam Bayrouti3, Ali Gargouri4, Tahia Sellami-Boudawara2, Raja Mokdad-Gargouri5.   

Abstract

Gastric carcinoma (GC) is a highly aggressive malignancy with poor prognosis. It is widely accepted that malignancy results from abnormal cell growth due to dysregulation of the balance between cell proliferation and apoptosis. Our study aimed to investigate the clinicopathological and prognostic significance of p53, Ki-67, and Bcl-2 in Tunisian GC patients by immunohistochemistry. It was observed that the older patients showed p53 overexpression compared with the younger patients (p<0.05). There was higher p53 expression in the intestinal-type compared with the diffuse-type (p<0.05), and in well/moderate differentiated than in poor differentiated tumors. The expression of Ki-67 was positively associated with tumor size and venous invasion (p<0.05). Bcl2 expression occurred in male patients and correlated with depth of invasion (p=0.02). A Kaplan-Meier analysis indicated an inverse correlation between p53 and Ki-67 expression and the overall survival. Multivariate analysis revealed that the tumor site, Ki-67 and p53 expression were independent prognostic factors for gastric carcinomas (p<0.05). Finally, combined expression of p53, Ki-67 and Bcl-2 showed that the group of patients with tumors p53+/Ki-67+/Bcl2- had aggressive behavior and poor prognosis (p log rank=0.000). In summary, our data indicated that the expression of p53, Ki-67, and Bcl-2 may provide useful information for identifying patients with aggressive behavior and poor prognosis of GC.
Copyright © 2014 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Bcl-2; Gastric carcinoma; Prognosis; ki-67; p53

Mesh:

Substances:

Year:  2014        PMID: 25095748     DOI: 10.1016/j.acthis.2014.07.008

Source DB:  PubMed          Journal:  Acta Histochem        ISSN: 0065-1281            Impact factor:   2.479


  6 in total

Review 1.  Clinicopathologic significance and prognostic value of Ki-67 expression in patients with gastric cancer: a meta-analysis.

Authors:  Guanying Luo; Yunzhao Hu; Zhiqiao Zhang; Peng Wang; Zhaowen Luo; Jinxin Lin; Canchang Cheng; You Yang
Journal:  Oncotarget       Date:  2017-07-25

2.  Clinicopathological and prognostic significance of Ki-67 immunohistochemical expression in gastric cancer: a systematic review and meta-analysis.

Authors:  Gang Liu; Disheng Xiong; Junjie Zeng; Borong Chen; Zhengjie Huang
Journal:  Onco Targets Ther       Date:  2017-09-01       Impact factor: 4.147

3.  Eph A10-modified pH-sensitive liposomes loaded with novel triphenylphosphine-docetaxel conjugate possess hierarchical targetability and sufficient antitumor effect both in vitro and in vivo.

Authors:  Jiulong Zhang; Chunrong Yang; Shuang Pan; Menghao Shi; Jie Li; Haiyang Hu; Mingxi Qiao; Dawei Chen; Xiuli Zhao
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

4.  Development of Triptolide Self-Microemulsifying Drug Delivery System and Its Anti-tumor Effect on Gastric Cancer Xenografts.

Authors:  Minghua Xie; Jia Wu; Liqaing Ji; Xiaorui Jiang; Jin Zhang; Min Ge; Xinjun Cai
Journal:  Front Oncol       Date:  2019-10-03       Impact factor: 6.244

5.  Ki-67/MKI67 as a Predictive Biomarker for Clinical Outcome in Gastric Cancer Patients: an Updated Meta-analysis and Systematic Review involving 53 Studies and 7078 Patients.

Authors:  Dan-Dan Xiong; Chu-Mei Zeng; Ling Jiang; Dian-Zhong Luo; Gang Chen
Journal:  J Cancer       Date:  2019-08-29       Impact factor: 4.207

6.  RIP140 and LCoR expression in gastrointestinal cancers.

Authors:  Mouna Triki; Dorra Ben Ayed-Guerfali; Ines Saguem; Slim Charfi; Lobna Ayedi; Tahia Sellami-Boudawara; Vincent Cavailles; Raja Mokdad-Gargouri
Journal:  Oncotarget       Date:  2017-11-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.